Announcement of the resolution of the second session of the 10th board of directors
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Pro 2018-001
Bond Abbreviation: 13 Peak 01 Bond Code: 122227
Bond Abbreviation: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
10th Session 2 Board Resolution Announcement
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and shall bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
1. Board Meeting
(I) The convening and convening of this board meeting complies with relevant laws, regulations and the company's "Articles of Association.
(II) 2018# On January 15, 29, the company issued the notice of the board meeting by fax, e-mail and personal service.
(III) 2018On January 19, the board meeting was held by means of a communication vote.
(IV) company has nine directors and nine directors participating in the voting.Deliberation of 2. Board Meeting
1
, "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical"
After deliberation and voting, the board of directors passed the proposal.The result of the vote was: 9
votes in favor, 0 votes against, and 0 abstentions.
For details, please refer to "Announcement on Foreign Investment of Subsidiary Jianfeng Pharmaceutical" (P.2018 -002)
Independent directors of the company expressed independent opinions on the investment matter, believing that the voting procedure of(1
) company's deliberation on "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical" conforms to the provisions of relevant laws, regulations and the company's Articles of Association, the decision-making process is legal and effective. The transaction follows the principles of fairness, openness and impartiality, and the pricing is fair and reasonable, and there is no harm to the interests of the company and shareholders.
(2) The parties to the transaction jointly commissioned Kunyuan Asset Appraisal Company Limited, which is qualified to practice securities, to evaluate the subject matter of the investment and issued the "Asset Appraisal Report" (Kunyuan Appraisal Report [2017] No. 1-37) . The appraisal agency is qualified to practice securities and futures, the appraisal agency's ability to meet the requirements of this appraisal work, and the appraisal process is independent.
(3) The relevant materials of the above-mentioned foreign investment items are fully prepared. We believe that the foreign investment items are in line with the company's development strategy. Jianfeng Pharmaceutical will use Shanghai Beika and its subsidiaries as platforms to establish R & D and production bases of raw materials and intermediates to further extend and improve the industrial chain of pharmaceutical business, which is conducive to increasing the scale of the company's pharmaceutical industry and improving the R & D capability of Jianfeng Pharmaceutical, it is conducive to enhancing the comprehensive strength of the peak pharmaceutical industry. agreed to the company's foreign investment matters.
Annex1
of the 3. Online Announcement, and the opinions of the 10th Independent Directors of the Company on the above related matters.
is hereby announcedZhejiang Jianfeng Group Co., Ltd. Board of Directors
January 19, 2018
More information
On the afternoon of June 9, Peak Cable Company organized all employees to learn fire fighting knowledge and conducted fire fighting and emergency escape drills. Since June, the subordinate enterprises of the company have organized training, learning and drills related to production safety according to their own characteristics and combined with the actual work. Safety production month series of activities carried out in an orderly manner.
2022
06-13
Spike Postdoctoral Research Papers on International Frontier Journals
Recently, good news came from the postdoctoral workstation of Jianfeng Pharmaceutical. Under the guidance of workstation mentor Jiang Xiaomeng, associate researcher Yang Xiaoxiao has made new progress in the treatment of alcoholic liver disease. The relevant research results "Roxadustat, a hypoxia-inducible factor 1a activator, attenuates both long- and short-term alcohol induced alcoholic liver disease" were published in the internationally renowned academic journal "Frontiers in Pharmacology. This journal is a frontier journal in the field of international pharmacy, mainly publishing academic papers and information on basic and clinical pharmacology, medicinal chemistry, pharmacology and toxicology.
2022
06-01
Daye Peak QC Achievements Won the Third Prize of Huangshi City
On May 7, Huangshi City Quality Strong City Working Committee organized a 2022 QC Results Conference. The QC project of "Technical Transformation of Ore Limestone Batching System" of Daye Peak Cement Company won the third prize.
2022
06-01
On April 28, Dalian Commodity Exchange held an online working meeting to announce the results of the 2021 excellent delivery warehouse and delivery warehouse excellent futures personnel selection, peak international trading company won the 2021 "excellent designated delivery warehouse" title, futures commissioner Ruan Weihang won the "excellent futures personnel" title.
2022
06-01
Cranberry extract combination identification detection method won the invention patent
After cranberry extract products were included in the "Zhejiang Province Key High-tech Product Development Project Plan" in 2021, Jianfeng Health Technology Company recently obtained an invention patent for the identification and detection method of cranberry extract. This new combined identification and detection method developed by Jianfeng Health identifies whether catechin or procyanidin B2 is added in cranberry extract by thin layer analysis, and then detects the unique A- type procyanidin and its chromatographic distribution in cranberry extract by high performance liquid chromatography, so as to improve the accuracy of product judgment. The identification method has the characteristics of accurate results and short detection time, which is of great significance to standardize the cranberry extract market and promote the healthy development of the industry, and has been unanimously recognized by peers.
2022
05-20
Daye Peak Manufacturing Department Won the Title of "Worker Pioneer" in Hubei Province
A few days ago, the manufacturing department of Daye Peak Cement Company was awarded the title of "Worker Pioneer" by the Hubei Provincial Federation of Trade Unions. Daye Jianfeng Manufacturing Department not only continued to actively explore and achieved good results in energy saving and consumption reduction, technological transformation, product quality process control, and economic responsibility system to guide management, but also improved Daye Jianfeng's overall operation level and won Huangshi City The seventh "Mayor Quality Award" created conditions and was fully affirmed by government departments at all levels.
2022
05-20
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page